CDS-KNRaj Library

Updates from K.N. Raj Library, CDS, Thiruvananthapuram

Two TRIPs to Innovation: Pharmaceutical Innovation Systems in India and Brazil by Verena Schüren

SFB-Governance Working Paper Series • No. 37 • June 2012 Abstract So far, the implementation of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) and the dynamics of innovation systems have been discussed fairly separately from each other. Research on TRIPs implementation has tended to focus on the (non-) adoption of certain TRIPs [...]

Foreign Firms, Indian Multinationals and Spillovers in the Indian Pharmaceutical Industry CG Iyer – Indian Growth and Development Review, 2012

Foreign firms and domestic multinationals have certain internal advantages which may spillover to domestic firms. However, due to heterogeneity across multinationals, it is not necessary that the effect of the spillovers generated by the foreign firm and that generated by the domestic multinational be similar. The purpose of this paper is to empirically find out [...]

Journal of Health Economics,vOL.31(2),March 2012

CONTENTS Evergreening, patent challenges, and effective market life in pharmaceuticals By C. Scott Hemphill, Bhaven N. Sampat The effect of a hospital nurse staffing mandate on patient health outcomes: Evidence from California’s minimum staffing regulation By Andrew Cook, Martin Gaynor, Melvin Stephens Jr, Lowell Taylor Watchfully waiting: Medical intervention as an optimal investment decision By Elisabeth Meyer, Ray [...]

The RAND Journal of Economics,Volume 43, Issue 1,Spring 2012

Contents Competition for attention in the Information (overload) Age (pages 1–25) By Simon P. Anderson and André de Palma Vertical control of a distribution network—an empirical analysis of magazines (pages 26–50) By Stijn Ferrari and Frank Verboven Accidental death and the rule of joint and several liability (pages 51–77) By Daniel Carvell, Janet Currie and [...]

Pharmaceutical patents and prices : a preliminary empirical assessment using data from India

by Mark Duggan and Aparajita Goyal WB Policy Research Paper No.6063, May 2012 The enforcement of stringent intellectual property rights in the pharmaceutical sector of developing countries generates considerable controversy, due to both the extensive research investment and the public policy importance of this sector. This paper explores the likely effects of enforcing product patents [...]

Policy Reforms in the Indian Pharmaceutical Sector since 1994Impact on Exports and Imports

by Reji K Joseph Economic and Political Weekly, May 05, 2012 Liberalisation measures in the pharmaceutical sector have brought about major changes in the industrial licensing policy, import restrictions, foreign direct investment and production controls. It was feared that firms would shift from indigenous production to imports, especially of bulk drugs, and this concern was [...]

Multinationals and Monopolies Pharmaceutical Industry in India after TRIPS

by Sudip Chaudhury EPW, March 24, 2012 In January 2005, drug product patent protection was reintroduced in India to comply with the agreement on Trade Related Aspects of Intellectual Property Rights.How are the multinational pharmaceutical companies responding to the new policy environment? Is India likely to see monopolisation of the industry and highprices, which was [...]

Journal of Health Economics, Volume 30, Issue 6, December 2011

Research Papers ·         Competition and the Reference Pricing Scheme for pharmaceuticals Simone Ghislandi ·         Does price reveal poor-quality drugs? Evidence from 17 countries Roger Bate, Ginger Zhe Jin, Aparna Mathur ·         State and self investments in health Eleonora Fichera, Matt Sutton ·         Rising educational gradients in mortality: The role of behavioral risk factors David M. [...]

The R&D Scenario in Indian Pharmaceutical Industry

by Reji K Joseph RIS Discussion Paper No.176, December 2011 A set of policy reforms have been introduced in the Indian pharmaceutical sector since mid-1990s, aimed at incentivizing the private sector R&D. Patent reforms was the most significant policy reform. An implicit assumption that the Indian pharmaceutical firms have become capable of developing new drugs [...]

Determinants of drug launch delay in pre-TRIPS India: A survival analysis approach

Saradindu Bhaduri and Thomas Brenner Working Paper # 05.11 Date: Dec-2011 The dynamics of drug launch has been an under-researched area. Most of the studies in this field focus on developed countries, quite uniform in terms of disease profile and regulatory framework, and analyse whether stringency in regulation influences launch delay. Developing countries, in contrast, have [...]

Multinationals and Monopolies Pharmaceutical Industry in India after TRIPS

by Sudip Chaudhuri IIMC WPS No.685/November 2011 India abolished product patent protection in pharmaceuticals in 1972. Before 1972 the industry was underdeveloped and the MNCs charged very high prices for patented drugs. After 1972, the monopoly power of the MNCs was eliminated, the industry experienced rapid growth and India emerged as a major player in [...]

South-South Cooperation in Health and Pharmaceuticals: EmergingTrends in India-Brazil Collaborations

By Sachin Chaturvedi RIS-DP # 172, March 2011 India-Brazil partnership in the health sector is an area in which the two major economies have increasingly collaborated not only bilaterally, but also in several international forums. This has added new thrust to the process of South-South cooperation. At the bilateral level, both the countries have identified [...]

  • Calendar

    May 2013
    M T W T F S S
    « Apr    
     12345
    6789101112
    13141516171819
    20212223242526
    2728293031  

  • Archives

  • Meta